Tags

Type your tag names separated by a space and hit enter

Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction.
PLoS One. 2010 Oct 18; 5(10):e13487.Plos

Abstract

BACKGROUND

Both fish oil and montelukast have been shown to reduce the severity of exercise-induced bronchoconstriction (EIB). The purpose of this study was to compare the effects of fish oil and montelukast, alone and in combination, on airway inflammation and bronchoconstriction induced by eucapnic voluntary hyperpnea (EVH) in asthmatics.

METHODS

In this model of EIB, twenty asthmatic subjects with documented hyperpnea-induced bronchoconstriction (HIB) entered a randomized double-blind trial. All subjects entered on their usual diet (pre-treatment, n = 20) and then were randomly assigned to receive either one active 10 mg montelukast tablet and 10 placebo fish oil capsules (n = 10) or one placebo montelukast tablet and 10 active fish oil capsules totaling 3.2 g EPA and 2.0 g DHA (n = 10) taken daily for 3-wk. Thereafter, all subjects (combination treatment; n = 20) underwent another 3-wk treatment period consisting of a 10 mg active montelukast tablet or 10 active fish oil capsules taken daily.

RESULTS

While HIB was significantly inhibited (p<0.05) by montelukast, fish oil and combination treatment compared to pre-treatment, there was no significant difference (p>0.017) between treatment groups; percent fall in forced expiratory volume in 1-sec was -18.4 ± 2.1%, -9.3±2.8%, -11.6 ± 2.8% and -10.8 ± 1.7% on usual diet (pre-treatment), fish oil, montelukast and combination treatment respectively. All three treatments were associated with a significant reduction (p<0.05) in F(E)NO, exhaled breathe condensate pH and cysteinyl-leukotrienes, while the fish oil and combination treatment significantly reduced (p<0.05) urinary 9α, 11β-prostaglandin F(2) after EVH compared to the usual diet; however, there was no significant difference (p>0.017) in these biomarkers between treatments.

CONCLUSION

While fish oil and montelukast are both effective in attenuating airway inflammation and HIB, combining fish oil with montelukast did not confer a greater protective effect than either intervention alone. Fish oil supplementation should be considered as an alternative treatment for EIB.

TRIAL REGISTRATION

ClinicalTrials.gov NCT00676468.

Authors+Show Affiliations

Human Performance and Exercise Biochemistry Laboratory, Department of Kinesiology, Indiana University, Bloomington, Indiana, United States of America.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20976161

Citation

Tecklenburg-Lund, Sandra, et al. "Randomized Controlled Trial of Fish Oil and Montelukast and Their Combination On Airway Inflammation and Hyperpnea-induced Bronchoconstriction." PloS One, vol. 5, no. 10, 2010, pp. e13487.
Tecklenburg-Lund S, Mickleborough TD, Turner LA, et al. Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction. PLoS ONE. 2010;5(10):e13487.
Tecklenburg-Lund, S., Mickleborough, T. D., Turner, L. A., Fly, A. D., Stager, J. M., & Montgomery, G. S. (2010). Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction. PloS One, 5(10), e13487. https://doi.org/10.1371/journal.pone.0013487
Tecklenburg-Lund S, et al. Randomized Controlled Trial of Fish Oil and Montelukast and Their Combination On Airway Inflammation and Hyperpnea-induced Bronchoconstriction. PLoS ONE. 2010 Oct 18;5(10):e13487. PubMed PMID: 20976161.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction. AU - Tecklenburg-Lund,Sandra, AU - Mickleborough,Timothy D, AU - Turner,Louise A, AU - Fly,Alyce D, AU - Stager,Joel M, AU - Montgomery,Gregory S, Y1 - 2010/10/18/ PY - 2010/04/14/received PY - 2010/08/12/accepted PY - 2010/10/27/entrez PY - 2010/10/27/pubmed PY - 2011/3/8/medline SP - e13487 EP - e13487 JF - PloS one JO - PLoS ONE VL - 5 IS - 10 N2 - BACKGROUND: Both fish oil and montelukast have been shown to reduce the severity of exercise-induced bronchoconstriction (EIB). The purpose of this study was to compare the effects of fish oil and montelukast, alone and in combination, on airway inflammation and bronchoconstriction induced by eucapnic voluntary hyperpnea (EVH) in asthmatics. METHODS: In this model of EIB, twenty asthmatic subjects with documented hyperpnea-induced bronchoconstriction (HIB) entered a randomized double-blind trial. All subjects entered on their usual diet (pre-treatment, n = 20) and then were randomly assigned to receive either one active 10 mg montelukast tablet and 10 placebo fish oil capsules (n = 10) or one placebo montelukast tablet and 10 active fish oil capsules totaling 3.2 g EPA and 2.0 g DHA (n = 10) taken daily for 3-wk. Thereafter, all subjects (combination treatment; n = 20) underwent another 3-wk treatment period consisting of a 10 mg active montelukast tablet or 10 active fish oil capsules taken daily. RESULTS: While HIB was significantly inhibited (p<0.05) by montelukast, fish oil and combination treatment compared to pre-treatment, there was no significant difference (p>0.017) between treatment groups; percent fall in forced expiratory volume in 1-sec was -18.4 ± 2.1%, -9.3±2.8%, -11.6 ± 2.8% and -10.8 ± 1.7% on usual diet (pre-treatment), fish oil, montelukast and combination treatment respectively. All three treatments were associated with a significant reduction (p<0.05) in F(E)NO, exhaled breathe condensate pH and cysteinyl-leukotrienes, while the fish oil and combination treatment significantly reduced (p<0.05) urinary 9α, 11β-prostaglandin F(2) after EVH compared to the usual diet; however, there was no significant difference (p>0.017) in these biomarkers between treatments. CONCLUSION: While fish oil and montelukast are both effective in attenuating airway inflammation and HIB, combining fish oil with montelukast did not confer a greater protective effect than either intervention alone. Fish oil supplementation should be considered as an alternative treatment for EIB. TRIAL REGISTRATION: ClinicalTrials.gov NCT00676468. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/20976161/Randomized_controlled_trial_of_fish_oil_and_montelukast_and_their_combination_on_airway_inflammation_and_hyperpnea_induced_bronchoconstriction_ L2 - http://dx.plos.org/10.1371/journal.pone.0013487 DB - PRIME DP - Unbound Medicine ER -